A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement

NCT ID: NCT07220967

Last Updated: 2025-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

392 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-21

Study Completion Date

2027-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The researchers are doing this study to find out whether Stimulan Rapid Cure works to reduce the risk of infections in people getting tissue expanders placed during mastectomy. The researchers will also study whether Stimulan Rapid Cure affects the risk of seroma, a possible complication of surgery that involves fluid buildup under the skin.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a randomized controlled study to compare the outcomes of immediate tissue expander (TE)-based breast reconstruction with and without antibiotic beads.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients randomized to Tissue Expander (TE) + antibiotic beads

Group Type EXPERIMENTAL

Tissue Expander (TE)

Intervention Type PROCEDURE

Tissue Expander (TE)

Vancomycin and Gentamicin

Intervention Type DRUG

Given through Stimulan Rapid Cure during surgery

Stimulan Rapid Cure

Intervention Type DEVICE

Vancomycin and Gentamicin given through Stimulan Rapid Cure during surgery

Patients randomized to Tissue Expander (TE) only

Group Type ACTIVE_COMPARATOR

Tissue Expander (TE)

Intervention Type PROCEDURE

Tissue Expander (TE)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tissue Expander (TE)

Tissue Expander (TE)

Intervention Type PROCEDURE

Vancomycin and Gentamicin

Given through Stimulan Rapid Cure during surgery

Intervention Type DRUG

Stimulan Rapid Cure

Vancomycin and Gentamicin given through Stimulan Rapid Cure during surgery

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female sex
* Aged 18 years or older
* Planned to undergo mastectomy for breast cancer, genetic predisposition to and/or strong family history of breast cancer, or other prophylactic indication
* Planned to undergo unilateral or bilateral immediate breast reconstruction (i.e., reconstruction at the time of mastectomy) with prepectoral TE placement at MSK
* BMI less than 40 kg/m2
* Not actively smoking or using other nicotine products within 6 weeks of surgery
* No contraindications to Stimulan antibiotic bead placement: hypercalcemia, severe vascular or neurological disease, uncontrolled diabetes, pregnancy, and severe degenerative bone disease
* No known allergy to calcium sulfate, vancomycin, or gentamicin
* No impaired decision-making capacity
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Danielle Rochlin, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States

Site Status RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, United States

Site Status RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States

Site Status RECRUITING

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

Commack, New York, United States

Site Status RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States

Site Status RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activites)

New York, New York, United States

Site Status RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activites)

Rockville Centre, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Danielle Rochlin, MD

Role: CONTACT

646-608-8033

Babak Mehrara, MD

Role: CONTACT

646-608-8639

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Danielle Rochlin, MD

Role: primary

646-608-8033

Danielle Rochlin, MD

Role: primary

646-608-8033

Danielle Rochlin, MD

Role: primary

646-608-8033

Danielle Rochlin, MD

Role: primary

646-608-8033

Danielle Rochlin, MD

Role: primary

646-608-8033

Danielle Rochlin, MD

Role: primary

646-608-8033

Danielle Rochlin, MD

Role: primary

646-608-8033

Related Links

Access external resources that provide additional context or updates about the study.

https://www.mskcc.org/

Memorial Sloan Kettering Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

25-278

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.